4HG0 Stock Chart & Stats
€0.25
-€0.01(-8.07%)
At close: 4:00 PM EST
€0.25
-€0.01(-8.07%)
Day’s Range― - ―
52-Week Range€0.09 - €0.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.15M
Enterprise Value€45.84
Total Cash (Recent Filing)€4.36M
Total Debt (Recent Filing)€8.35M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding28,874,178
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-11.77
Revenue Forecast (FY)€10.82M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthThe sharp increase in trailing revenue indicates growing commercial activity and potential customer adoption of the diagnostic offering. Although it starts from a small base, continued expansion could improve operating leverage and strengthen the installed base over the next several quarters.
Positive Equity PositionThe return to positive equity represents a meaningful balance-sheet stabilization after several years of negative equity. This provides a stronger capital base than before, potentially improving resilience and supporting continued development while management works toward commercial scale.
Recurring Consumables ModelA platform paired with single-use cartridges can create repeat purchasing as instruments are deployed and used. This installed-base model may support more durable revenue than one-time equipment sales, while service and collaboration income offer additional commercialization channels.
Bears Say
Persistent Cash BurnMaterially negative operating and free cash flow shows that the company is not yet self-funding its operations. Continued cash burn can constrain investment, increase dependence on external capital, and make execution more vulnerable if revenue growth does not translate into cash generation.
Severe UnprofitabilityExtremely negative margins indicate that the current business has not reached an economically sustainable operating scale. Persistent losses can absorb capital and limit flexibility, while the gap between revenue growth and profitability suggests that scaling the model remains a substantial challenge.
High Leverage And Financing RiskDebt remains high relative to the current equity base, limiting financial flexibility while losses continue. The history of negative equity increases the risk that ongoing funding needs could require refinancing or shareholder dilution, potentially weakening the company’s long-term capital structure.
4HG0 FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was €0.09 and its highest was €0.28 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is €4.15M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Nov 11, 2026 which is in 43 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on Aug 26, 2026. The company reported -€0.021 earnings per share for the quarter.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -€0.021 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in DE:4HG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.